Fairmount Funds Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Fairmount Funds Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-886,281	Closed	-$15.6M	–	21
2021 Q3	$15.6M	Sell	886,281 -10,000	-1%	-$117K	5.66%	7
2021 Q2	$8.69M	Sell	896,281 -426,900	-32%	-$4.02M	3.57%	12
2021 Q1	$14.2M	Sell	1,323,181 -155,000	-10%	-$1.92M	5.99%	6
2020 Q4	$21.7M	Sell	1,478,181 -80,000	-5%	-$1.15M	7.78%	5
2020 Q3	$22.1M	Buy	1,558,181 +75,000	+5%	+$748K	9.38%	3
2020 Q2	$12M	Sell	1,483,181 -335,000	-18%	-$2.07M	5.35%	10
2020 Q1	$7.34M	Buy	+1,818,181	New	+$6.87M	4.45%	12

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Fairmount Funds Management's TRIL Position: Q4 2021 in Review

Fairmount Funds Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 886,281 shares — an estimated $15.6M sold.

Fairmount Funds Management first reported a position in TRIL in Q1 2020 and held it in 7 quarters. The position peaked at $22.1M in Q3 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Fairmount Funds Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Fairmount Funds Management sold 886,281 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $15.6M.
Fairmount Funds Management first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 7 quarters.
Fairmount Funds Management's Trillium Therapeutics Inc. position peaked at $22.1M in Q3 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Fairmount Funds Management's 13F filing for Q4 2021, filed 14 Feb 2022.